Want to see STAA full AI Analyst Report?
STAA Stock Chart & Stats
$22.39
-$0.28(-1.20%)
At close: 4:00 PM EDT
$22.39
-$0.28(-1.20%)
Day’s Range― - ―
52-Week Range$15.59 - $35.87
Previous CloseN/A
Volume242.83K
Average Volume (3M)932.19K
Market Cap
$1.18B
Enterprise Value$1.29K
Total Cash (Recent Filing)$181.49M
Total Debt (Recent Filing)$35.94M
Price to Earnings (P/E)288.9
Beta1.12
Next Earnings
Nov 04, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.08
Shares Outstanding50,143,986
10 Day Avg. Volume677,169
30 Day Avg. Volume932,194
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)3.40
Price to Sales (P/S)4.89
P/FCF Ratio-29.21
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$29.67Price Target Upside32.50% Upside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)0.33
Revenue Forecast (FY)$334.63M
Bulls Say, Bears Say
Bulls Say
Global Revenue GrowthBroad-based growth across China, APAC, the Americas and EMEA shows expanding adoption of STAAR’s lens-based refractive surgery platform. Geographic diversification can support durable demand and reduce reliance on any single market over the next several quarters.
High Margins And No DebtVery high gross margins indicate strong product economics, while the debt-free balance sheet provides flexibility to fund manufacturing expansion, product development and market growth. This financial capacity also reduces refinancing risk during periods of earnings volatility.
Established ICL PlatformA large installed base, global distribution and decades of clinical experience create meaningful credibility with surgeons and patients. Continued Collamer development and next-generation products can reinforce differentiation beyond the current ICL portfolio.
Bears Say
Weak Cash GenerationNegative recent operating and free cash flow limits internally generated funding despite the strong cash balance. If profitability or working-capital performance remains uneven, the company may need to rely more heavily on existing liquidity to support growth and investment.
Manufacturing Capacity ConstraintsPersistent capacity shortfalls can delay procedures, limit product adoption and weaken relationships with distributors and surgeons. Scaling made-to-order production while broadening EVO Plus availability is essential to convert strong demand into sustained revenue.
Tariff And Regional ExposureThe business remains exposed to trade costs, manufacturing transition risk and pronounced China seasonality. Until Swiss production is fully established, tariffs may constrain margins, while regional variability can make revenue and resource planning less predictable.
Staar Surgical News
STAA FAQ
What was Staar Surgical’s price range in the past 12 months?
Staar Surgical lowest stock price was $15.59 and its highest was $35.87 in the past 12 months.
What is Staar Surgical’s market cap?
Staar Surgical’s market cap is $1.18B.
When is Staar Surgical’s upcoming earnings report date?
Staar Surgical’s upcoming earnings report date is Nov 04, 2026 which is in 62 days.
How were Staar Surgical’s earnings last quarter?
Staar Surgical released its earnings results on Aug 12, 2026. The company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.221 by -$0.061.
Is Staar Surgical overvalued?
According to Wall Street analysts Staar Surgical’s price is currently Undervalued.
Does Staar Surgical pay dividends?
Staar Surgical does not currently pay dividends.
What is Staar Surgical’s EPS estimate?
Staar Surgical’s EPS estimate is 0.05.
How many shares outstanding does Staar Surgical have?
Staar Surgical has 50,143,986 shares outstanding.
What happened to Staar Surgical’s price movement after its last earnings report?
Staar Surgical reported an EPS of $0.16 in its last earnings report, missing expectations of $0.221. Following the earnings report the stock price went down -0.315%.
Which hedge fund is a major shareholder of Staar Surgical?
Currently, no hedge funds are holding shares in STAA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Staar Surgical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$29.67 (32.50% Upside)
$29.67 (32.50% Upside)
Blogger Sentiment
Bullish
STAA Sentiment 60%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 225.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.69%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
8.55%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Staar Surgical
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.
STAA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted a strong operational and financial recovery: record first-half revenue, significant YoY top-line growth (Q2 net sales +111%), return to profitability (net income $8.1M; adjusted EBITDA $20M), improved cash balance and strategic progress on product launches (EVO Plus) and ERP deployment. Key risks remain—supply constraints (EVO Plus demand outstripping capacity), tariff-related margin pressure until Swiss manufacturing is fully ramped, regional seasonality and market variability (China seasonality, EMEA/Middle East impacts), and near-term ERP and transition costs. On balance the positive financial turnaround, market share gains in China, and clear roadmap for innovation outweigh the operational headwinds.View all STAA earnings summariesSTAA Stock 12 Month Forecast
Average Price Target
$29.67
▲(32.50% Upside)









